<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17474" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Amoxicillin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Akhavan</surname>
            <given-names>Bobak J.</given-names>
          </name>
          <aff>Un of Texas at Houston, McGovern MS</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khanna</surname>
            <given-names>Niloufar R.</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vijhani</surname>
            <given-names>Praveen</given-names>
          </name>
          <aff>UTHSC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bobak Akhavan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Niloufar Khanna declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Praveen Vijhani declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17474.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Amoxicillin is a widely utilized beta-lactam antimicrobial drug approved by the U.S. Food and Drug Administration (FDA) for use in the primary care setting. Amoxicillin is&#x000a0;an aminopenicillin created by adding an extra amino group to penicillin to battle antibiotic resistance. This drug is indicated for the treatment of infections caused by susceptible isolates of selected bacteria, specifically those that are beta-lactamase&#x02013;negative, including ear, nose, and throat infections, <italic toggle="yes">Helicobacter pylori&#x000a0;</italic>eradication, lower respiratory and urinary tract infections,&#x000a0;acute bacterial sinusitis, and skin and&#x000a0;structure infections.</p>
        <p>Amoxicillin is effective against a wide range of gram-positive bacteria, offering additional coverage against some gram-negative organisms compared to penicillin.&#x000a0;Amoxicillin's spectrum of activity includes coverage against <italic toggle="yes">Streptococcus</italic> species, with heightened efficacy against <italic toggle="yes">Listeria monocytogenes</italic> and <italic toggle="yes">Enterococcus</italic> spp. Furthermore, amoxicillin also demonstrates effectiveness against <italic toggle="yes">Haemophilus influenzae</italic>, select <italic toggle="yes">Escherichia coli</italic> strains, <italic toggle="yes">Actinomyces</italic> spp., <italic toggle="yes">Clostridium</italic> species, <italic toggle="yes">Salmonella</italic> spp., <italic toggle="yes">Shigella</italic> spp., and <italic toggle="yes">Corynebacteria</italic> spp.&#x000a0;This activity delves into the indications, mechanism of action, administration, contraindications, and adverse event profiles associated with amoxicillin. This activity equips clinicians with a comprehensive understanding of amoxicillin&#x000a0;to optimally enhance their ability to manage infectious diseases in patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate between the spectrum of activity of amoxicillin and other antimicrobial agents, understanding its coverage against various gram-positive and some gram-negative organisms compared to penicillin.</p></list-item><list-item><p>Implement effective antimicrobial stewardship practices by selecting amoxicillin judiciously, considering its efficacy against specific bacteria causing the infection, and minimizing the risk of contributing to antimicrobial resistance.</p></list-item><list-item><p>Select amoxicillin as a preferred agent for susceptible bacterial infections, considering its effectiveness against common pathogens and safety profile.</p></list-item><list-item><p><bold>Collaborate</bold>&#x000a0;with other healthcare professionals to promote antimicrobial stewardship, enhancing outcomes and treatment efficacy for patients who might benefit from amoxicillin therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17474&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17474">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17474.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Amoxicillin is a widely utilized beta-lactam antimicrobial drug approved by the U.S. Food and Drug Administration (FDA) for use in the primary care setting. Amoxicillin is&#x000a0;an aminopenicillin created by adding an extra amino group to penicillin to battle antibiotic resistance. The medication is effective against a wide range of gram-positive bacteria, offering additional coverage against some gram-negative organisms compared to penicillin.&#x000a0;Amoxicillin's spectrum of activity includes coverage against&#x000a0;<italic toggle="yes">Streptococcus</italic>&#x000a0;species, with heightened efficacy against&#x000a0;<italic toggle="yes">Listeria monocytogenes</italic>&#x000a0;and&#x000a0;<italic toggle="yes">Enterococcus</italic>&#x000a0;spp.&#x000a0;Furthermore, amoxicillin also demonstrates effectiveness against&#x000a0;<italic toggle="yes">Haemophilus influenzae</italic>, select&#x000a0;<italic toggle="yes">Escherichia coli</italic>&#x000a0;strains,&#x000a0;<italic toggle="yes">Actinomyces</italic>&#x000a0;spp.,&#x000a0;<italic toggle="yes">Clostridium</italic>&#x000a0;species,&#x000a0;<italic toggle="yes">Salmonella</italic>&#x000a0;spp.,&#x000a0;<italic toggle="yes">Shigella</italic>&#x000a0;spp., and&#x000a0;<italic toggle="yes">Corynebacteria</italic>&#x000a0;spp.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Amoxicillin is indicated for treating infections caused by susceptible isolates of selected bacteria, specifically beta-lactamase&#x02013;negative,&#x000a0;in the conditions listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Ear, nose, and throat infections: Amoxicillin is approved for the treatment of tonsillitis, pharyngitis, and otitis media in adults and pediatric patients aged 12 and older.&#x000a0;The microbiological spectrum covers infections caused by beta-lactamase&#x02013;negative <italic toggle="yes">Streptococcus</italic> species (alpha- and beta-hemolytic isolates only), <italic toggle="yes">Streptococcus pneumoniae</italic>, <italic toggle="yes">Staphylococcus</italic> species, or <italic toggle="yes">H influenzae</italic>.<xref ref-type="bibr" rid="article-17474.r1">[1]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Helicobacter pylori&#x000a0;</italic>eradication:&#x000a0;<italic toggle="yes">H pylori</italic> eradication involves triple therapy using clarithromycin, amoxicillin, and lansoprazole to reduce the risk of duodenal ulcer recurrence. In addition, dual treatment with amoxicillin and lansoprazole is FDA-approved for eradicating&#x000a0;<italic toggle="yes">H</italic>&#x000a0;<italic toggle="yes">pylori </italic>infection.<xref ref-type="bibr" rid="article-17474.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lower respiratory tract infections: Amoxicillin is prescribed for treating lower respiratory tract&#x000a0;infections caused by beta-lactamase&#x02013;negative <italic toggle="yes">Streptococcus</italic> species (limited to alpha- and beta-hemolytic strains), <italic toggle="yes">Pneumococcus</italic> or&#x000a0;<italic toggle="yes">Staphylococcus</italic> species, or <italic toggle="yes">H influenzae</italic>. In cases of community-acquired pneumonia, the Infectious Diseases Society of America (IDSA) recommends a combination therapy comprising amoxicillin and a macrolide antibiotic.<xref ref-type="bibr" rid="article-17474.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acute bacterial sinusitis: The treatment for acute&#x000a0;bacterial&#x000a0;sinusitis involves addressing infections caused by beta-lactamase&#x02013;negative <italic toggle="yes">Streptococcus</italic> species (limited to alpha- and beta-hemolytic isolates),&#x000a0;<italic toggle="yes">S</italic>&#x000a0;<italic toggle="yes">pneumoniae</italic>,&#x000a0;<italic toggle="yes">Staphylococcus</italic>&#x000a0;<italic toggle="yes">species</italic>, or&#x000a0;<italic toggle="yes">H influenzae</italic>.<xref ref-type="bibr" rid="article-17474.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Skin and skin structure infections:&#x000a0;Amoxicillin in the&#x000a0;immediate-release formulation is prescribed to treat skin infections caused by beta-lactamase&#x02013;negative <italic toggle="yes">Streptococcus</italic> species (restricted to alpha- and beta-hemolytic strains),&#x000a0;<italic toggle="yes">Staphylococcus</italic>&#x000a0;<italic toggle="yes">species</italic>, or&#x000a0;<italic toggle="yes">E</italic>&#x000a0;<italic toggle="yes">coli</italic>.<xref ref-type="bibr" rid="article-17474.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Urinary tract infection:&#x000a0;Amoxicillin is indicated for treating genitourinary tract infections caused by beta-lactamase&#x02013;negative<italic toggle="yes">&#x000a0;E coli</italic>,&#x000a0;<italic toggle="yes">Proteus mirabilis,&#x000a0;</italic>or&#x000a0;<italic toggle="yes">Enterococcus faecalis</italic>.<xref ref-type="bibr" rid="article-17474.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>The Centers for Disease Control and Prevention (CDC) recommends using amoxicillin as a second-line agent for post-exposure prophylaxis for anthrax.<xref ref-type="bibr" rid="article-17474.r7">[7]</xref></p>
        <p>
<bold>Off-label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Amoxicillin is often used for Lyme&#x000a0;disease if there are contraindications for doxycycline.<xref ref-type="bibr" rid="article-17474.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Infectious endocarditis prophylaxis is recommended for individuals with high-risk cardiac conditions, such as a prosthetic cardiac valve or congenital heart disease, using amoxicillin.<xref ref-type="bibr" rid="article-17474.r9">[9]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Amoxicillin, combined with metronidazole, is used to treat&#x000a0;periodontitis.<xref ref-type="bibr" rid="article-17474.r10">[10]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Amoxicillin is often used for the treatment of actinomycosis.<xref ref-type="bibr" rid="article-17474.r11">[11]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17474.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Amoxicillin belongs to the class of beta-lactam antimicrobials. Beta-lactams bind to penicillin-binding proteins, inhibiting transpeptidation&#x000a0;&#x02014;&#x000a0;a crucial step in cell wall synthesis involving cross-linking. This action activates autolytic enzymes in the bacterial cell wall, resulting in cell wall lysis and bacterial cell destruction. This mechanism is known as bactericidal killing.<xref ref-type="bibr" rid="article-17474.r12">[12]</xref></p>
        <p>Amoxicillin administration can be combined with a beta-lactamase inhibitor, such as clavulanic acid or sulbactam. These inhibitors function by irreversibly binding to the catalytic site of the organism's beta-lactamase enzyme, preventing resistance to the original beta-lactam ring of amoxicillin. Although these inhibitors lack inherent bactericidal activity, their combination with amoxicillin may broaden its spectrum to include organisms producing the beta-lactamase enzyme.<xref ref-type="bibr" rid="article-17474.r13">[13]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Amoxicillin exhibits stability in the presence of gastric acid and is rapidly absorbed after oral administration, with average peak blood levels typically reached within 1 to 2 hours.</p>
        <p><bold>Distribution:</bold> Amoxicillin displays significant tissue and fluid diffusion throughout the body, with the exception of the brain and spinal fluid, except in cases where meningeal inflammation is present. Amoxicillin exhibits approximately 20% plasma protein binding.</p>
        <p><bold>Metabolism:</bold> The metabolism of amoxicillin involves oxidation, hydroxylation, and deamination processes. Amoxicillin is a substrate of organic anion transporters (OATs), specifically OATs 1 and 3.<xref ref-type="bibr" rid="article-17474.r14">[14]</xref><xref ref-type="bibr" rid="article-17474.r15">[15]</xref></p>
        <p><bold>Elimination:</bold> Amoxicillin has an approximate half-life of 61.3 minutes, and about 60% of the administered dose is excreted in the urine within 6 to 8 hours. Co-administration of probenecid can delay amoxicillin excretion, as the majority of the drug is eliminated unchanged in the urine.</p>
      </sec>
      <sec id="article-17474.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Bactericidal antimicrobials, such as amoxicillin, exhibit their greatest efficacy in a "time-dependent" manner rather than a "concentration-dependent" one. In the context of time-dependent action, the emphasis is on the duration during which serum concentrations exceed the minimum inhibitory concentration (MIC) for the targeted microorganism. Consequently, these antimicrobials are often administered more frequently than concentration-dependent drugs, which may have daily dosing regimens. The more frequent, "around-the-clock" dosing strategy aims to minimize variations in peak and trough serum concentrations.<xref ref-type="bibr" rid="article-17474.r16">[16]</xref><xref ref-type="bibr" rid="article-17474.r17">[17]</xref></p>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>Amoxicillin is administered orally and is available in various forms, including immediate-release or extended-release tablets, chewable tablets, and suspension. After thorough shaking, the medication can be mixed and administered with formula, milk, water, fruit juice, ginger ale, or other cold drinks. Immediate administration is recommended after mixing. Extended-release tablets should not be crushed, and administration should occur within 1 hour after completing a meal. Amoxicillin, with a more palatable taste, is often preferred over penicillin in pediatric patients. In contrast, ampicillin is versatile, structurally similar, and suitable for oral, intravenous, or intramuscular administration.</p>
        <p>
<bold>Amoxicillin Dosages&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adults: For adults, the recommended dosage of amoxicillin is 750 to 1750 mg/d, divided into doses and administered every 8 to 12 hours.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric:&#x000a0;For pediatric patients 3 months and older, the recommended amoxicillin dosage is 20 to 45 mg/kg/d, divided into doses and administered every 8 to 12 hours.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">H pylori</italic>&#x000a0;infection (triple therapy): For the treatment of <italic toggle="yes">H pylori</italic> infection, the recommended dosing for triple therapy involves administering 1 g of amoxicillin, 500 mg of clarithromycin, and 30 mg of lansoprazole twice daily (every 12 hours) for 14 days.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">H pylori</italic>&#x000a0;infection (dual therapy): For dual therapy against <italic toggle="yes">H pylori</italic> infection, the recommended dosing is 1 g of amoxicillin and 30 mg of lansoprazole, each administered 3 times daily.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>The product labeling does not recommend dosage adjustments for individuals with hepatic impairment.</p>
        <p><bold>Renal impairment:</bold> Patients with impaired renal function typically do not necessitate a dose reduction unless the impairment is severe. However, individuals with severe renal impairment, defined by a glomerular filtration rate of &#x0003c;30 mL/min, should not receive an 875-mg amoxicillin dose. Patients with a glomerular filtration rate of 10 to 30 mL/min should receive 500 mg or 250 mg of amoxicillin every 12 hours, depending on the severity of the infection. Patients with a glomerular filtration rate &#x0003c;10 mL/min should receive 500 or 250 mg of amoxicillin every 24 hours, depending on the severity of the infection. Hemodialysis patients should be prescribed 500 or 250 mg of amoxicillin every 24 hours, with the dosage adjusted based on the infection severity. An additional dose is recommended both during and after dialysis.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Amoxicillin is classified as a pregnancy category B drug under the former FDA classification system, indicating a lack of studies demonstrating clear risk. This medication is widely used in pregnant women, and available data generally support its compatibility during pregnancy.&#x000a0;The recommended dose and duration of amoxicillin therapy for pregnant and postpartum women align with those for nonpregnant adults.<xref ref-type="bibr" rid="article-17474.r18">[18]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>An&#x000a0;exclusively breastfed infant is anticipated to receive a maximum daily dosage of approximately 0.1 mg/kg of amoxicillin when the mother takes 500 mg thrice&#x000a0;daily. This represents only 0.25% to 0.5% of a typical infant amoxicillin dosage. As discussed above,&#x000a0;low levels of amoxicillin in breast milk are generally not anticipated to induce adverse effects in breastfed infants. Infrequent reports include rash and disturbances in the infant's gastrointestinal flora, leading to diarrhea or thrush. As a result, amoxicillin is considered acceptable for use in nursing mothers.<xref ref-type="bibr" rid="article-17474.r19">[19]</xref></p>
        <p><bold>Older patients:</bold>&#x000a0;Notably, as&#x000a0;amoxicillin is predominantly excreted through the kidneys, renal adjustments and additional caution may be warranted, especially in cases of renal insufficiency. Because older patients are more likely to have decreased renal function, the clinician should adjust the dosage. Amoxicillin&#x000a0;is reportedly partially dialyzable; therefore, immediate-release tablets can be an option for dosing after hemodialysis.<xref ref-type="bibr" rid="article-17474.r20">[20]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>The therapeutic efficacy and safety of amoxicillin have been established for treating skin and soft tissue infections, respiratory tract infections, and genitourinary tract infections in pediatric patients. In neonates and infants, the elimination of amoxicillin may be delayed due to their incompletely developed renal function. Thus, dosage adjustments are necessary for pediatric patients aged 12 weeks or younger (3 months or younger). Oral amoxicillin exhibits potential as a safe substitute for parenteral ampicillin in neonatal sepsis regimens that include aminoglycosides, particularly in cases where hospitalization is not feasible.<xref ref-type="bibr" rid="article-17474.r21">[21]</xref><bold/></p>
      </sec>
      <sec id="article-17474.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Common Adverse Drug Reactions</bold>
</p>
        <p>Although generally well-tolerated, amoxicillin may lead to common gastrointestinal symptoms, including nausea, vomiting, and diarrhea. Additional adverse drug reactions associated with amoxicillin are listed below.</p>
        <p><bold>Superinfections:&#x000a0;</bold>Mucocutaneous candidiasis and <italic toggle="yes">Clostridium difficile&#x02013;</italic>associated diarrhea (CDAD) are potential&#x000a0;adverse&#x000a0;effects of amoxicillin. Notably, individuals taking amoxicillin may experience less diarrhea than those taking ampicillin due to better absorption in the gut.<xref ref-type="bibr" rid="article-17474.r22">[22]</xref></p>
        <p><bold>Nephrotoxicity:</bold> Amoxicillin may cause crystalluria and interstitial nephritis.<xref ref-type="bibr" rid="article-17474.r23">[23]</xref><xref ref-type="bibr" rid="article-17474.r24">[24]</xref></p>
        <p><bold>Hypersensitivity</bold> r<bold>eactions</bold>: Amoxicillin has the potential to cause hypersensitivity reactions categorized as type I, II, III, or IV. Differentiating between a type-I and type-IV reaction is crucial due to varying danger levels. A type-I hypersensitivity reaction involves an IgE-mediated response in sensitized patients, inducing widespread histamine release, resulting in an urticarial-like pruritic rash or severe anaphylaxis.&#x000a0;In contrast, a&#x000a0;type-IV hypersensitivity reaction is not mediated by histamine release and typically presents as a more papular or morbilliform rash, often without itching. Notably,&#x000a0;almost all patients receiving amoxicillin inadvertently for infectious mononucleosis may develop a maculopapular rash attributed to a type IV&#x02013;mediated hypersensitivity reaction. Notably, reactions of this type are not associated with anaphylaxis.<xref ref-type="bibr" rid="article-17474.r25">[25]</xref></p>
        <p><bold>Hepatotoxicity:&#x000a0;</bold>Cases of idiosyncratic liver injury have been reported in individuals receiving amoxicillin. The associated serum enzyme pattern reveals a hepatocellular pattern characterized by significant elevations in aspartate transaminase (AST) and alanine transaminase (ALT), with minimal increases in alkaline phosphatase. Most patients experience rapid recovery upon withdrawal of amoxicillin. The cause of liver injury associated with amoxicillin use is attributed to hypersensitivity. Although rare, cases of acute liver failure and vanishing bile duct syndrome have been reported. Corticosteroids are often used to treat allergic reactions caused by penicillin-related immunoallergic hepatitis, which is a rare cause of clinically apparent liver injury, with a likelihood score of B.<xref ref-type="bibr" rid="article-17474.r26">[26]</xref></p>
        <p>
<bold>Postmarketing Adverse Drug Reactions</bold>
</p>
        <p><bold>Gastrointestinal</bold>: Gastrointestinal effects may include black hairy tongue, pseudomembranous colitis, and hemorrhagic colitis.<xref ref-type="bibr" rid="article-17474.r27">[27]</xref></p>
        <p><bold>Neurological</bold>:&#x000a0;Neurological effects may encompass reversible hyperactivity, agitation, anxiety, insomnia, confusion, convulsions, and aseptic meningitis.<xref ref-type="bibr" rid="article-17474.r28">[28]</xref></p>
        <p><bold>Hematological</bold>:&#x000a0;Hematological effects may include hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia, and neutropenia.<xref ref-type="bibr" rid="article-17474.r29">[29]</xref></p>
        <p><bold>Dermatological</bold>: Dermatological effects may manifest as serum sickness-like reactions, erythematous maculopapular rashes, exfoliative dermatitis, toxic epidermal necrolysis, and hypersensitivity vasculitis.<xref ref-type="bibr" rid="article-17474.r30">[30]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Concomitant use of probenecid diminishes the renal tubular secretion of amoxicillin, leading to increased and prolonged amoxicillin blood levels.<xref ref-type="bibr" rid="article-17474.r31">[31]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Amoxicillin can induce abnormal prolongation of prothrombin time (increased INR) in patients taking oral anticoagulants, requiring meticulous monitoring and potential dosage adjustments for anticoagulation.<xref ref-type="bibr" rid="article-17474.r32">[32]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Concurrent administration of amoxicillin and allopurinol increases the incidence of rashes compared to amoxicillin alone.<xref ref-type="bibr" rid="article-17474.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Amoxicillin may alter intestinal flora, leading to reduced estrogen reabsorption and potentially diminishing the efficacy of combined oral estrogen or progesterone contraceptives.<xref ref-type="bibr" rid="article-17474.r34">[34]</xref><xref ref-type="bibr" rid="article-17474.r35">[35]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chloramphenicol, macrolides, sulfonamides, and tetracyclines can interfere with the bactericidal effects of penicillin, although the clinical significance of this interaction is not extensively documented.<xref ref-type="bibr" rid="article-17474.r36">[36]</xref>&#x000a0;In general, clinicians are advised to avoid combining bacteriostatic and bactericidal drugs.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intravesical BCG therapy should not be administered concomitantly with antibiotics, including amoxicillin, to mitigate the potential risk of interference with the clinical response to intravesical BCG.<xref ref-type="bibr" rid="article-17474.r37">[37]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Laboratory Test Interactions</bold>
</p>
        <p>High urine concentrations of amoxicillin can cause false-positive reactions in urine glucose tests using certain detection methods. Clinicians should consider using alternative enzymatic glucose oxidase-based tests.</p>
      </sec>
      <sec id="article-17474.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Understanding contraindications and nuances related to amoxicillin use is crucial for healthcare professionals.&#x000a0;This overview explores contraindications stemming from previous anaphylactic reactions, considerations of crossover sensitivity, and the differentiation between type-I and type-IV hypersensitivity reactions in patients, offering insights into skin testing as a diagnostic tool.</p>
        <list list-type="bullet">
          <list-item>
            <p>Prior occurrences of anaphylactic reactions or severe skin responses, such as Stevens-Johnson syndrome, to amoxicillin or other beta-lactams are a contraindication to amoxicillin.<xref ref-type="bibr" rid="article-17474.r38">[38]</xref>&#x000a0;These reactions may have crossover sensitivity with cephalosporins or carbapenems. Recent data suggests significantly lower cross-reactivity with these agents than once suspected.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A critical consideration is distinguishing between type-I and type-IV hypersensitivity reactions when evaluating allergic rashes. Occasionally, patients may report a childhood allergy to amoxicillin, which is, in fact, a type-IV&#x02013;mediated hypersensitivity reaction, which is often associated with infectious mononucleosis. Importantly, this is not a contraindication for administering repeat amoxicillin. However, a type-I&#x02013;mediated hypersensitivity reaction constitutes a contraindication due to the risk of anaphylaxis upon repeat exposure.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Skin testing is approved to aid in identifying hypersensitivity to penicillins, with reports indicating that the risk of an allergic reaction in patients with a positive skin test is approximately 4%. In contrast, a negative skin test exhibits a relatively high sensitivity in excluding a type-I hypersensitivity reaction.<xref ref-type="bibr" rid="article-17474.r39">[39]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17474.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Ensuring the safe and effective use of amoxicillin involves attentive oversight. The essential monitoring considerations encompass hypersensitivity reactions, laboratory parameters during different courses of treatment, and potential adverse effects of amoxicillin, which require clinician evaluation. It is crucial to be vigilant for hypersensitivity reactions, and patients should promptly notify their physician of any developing rashes.<xref ref-type="bibr" rid="article-17474.r39">[39]</xref>&#x000a0;No specific laboratory monitoring parameters are suggested&#x000a0;for patients on a short-term course of amoxicillin. However, during prolonged administration, such as for osteomyelitis, it is essential to periodically monitor renal and hepatic function and hematologic function throughout the treatment.<xref ref-type="bibr" rid="article-17474.r26">[26]</xref>&#x000a0;Although mild diarrhea is often tolerable, prolonged diarrhea with fever and abdominal pain should prompt evaluation by a clinician for CDAD.<xref ref-type="bibr" rid="article-17474.r40">[40]</xref>&#x000a0;High doses of penicillin can induce seizures, raising concerns, especially in patients with renal failure.<xref ref-type="bibr" rid="article-17474.r41">[41]</xref></p>
      </sec>
      <sec id="article-17474.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>A prospective study of 51 pediatric patients at a poison control center suggested that amoxicillin overdoses of less than 250 mg/kg are not associated with significant clinical symptoms, as per the FDA product labeling.</p>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Interstitial nephritis leading to oliguric renal failure has been reported in a small number of patients following overdosage with amoxicillin.<xref ref-type="bibr" rid="article-17474.r23">[23]</xref><xref ref-type="bibr" rid="article-17474.r24">[24]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Crystalluria leading to renal failure has been reported in both adult and pediatric patients following amoxicillin overdosage.<xref ref-type="bibr" rid="article-17474.r42">[42]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Management of Overdose</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In case of amoxicillin overdose, clinicians should discontinue amoxicillin therapy and provide supportive care to patients.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clinicians should maintain the patient's airway, breathing, and circulation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Healthcare providers should ensure the patient maintains adequate fluid intake to mitigate the risk of amoxicillin crystalluria.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Renal impairment appears to be reversible with the cessation of drug administration.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Amoxicillin may be removed from circulation by hemodialysis.<xref ref-type="bibr" rid="article-17474.r43">[43]</xref><xref ref-type="bibr" rid="article-17474.r20">[20]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Individuals should contact a poison control center at 1-800-222-1222 for updated information about an amoxicillin overdose.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17474.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Amoxicillin is a commonly prescribed antimicrobial by nurse practitioners, primary care providers, and internists. Although amoxicillin is considered a safe drug,&#x000a0;it is crucial to obtain a thorough history of allergies before&#x000a0;prescribing the drug. Due to the widespread use of amoxicillin, healthcare providers should have a comprehensive understanding of its mechanism, resistance patterns, adverse drug reactions, and toxicity management.<xref ref-type="bibr" rid="article-17474.r39">[39]</xref><xref ref-type="bibr" rid="article-17474.r44">[44]</xref></p>
        <p>Amoxicillin therapy is typically initiated by the clinician for the appropriate indication. However, a pharmacist must verify the dosing and duration, ensuring accuracy for the specific infection being treated. The pharmacist should also confirm that no drug interactions could impede the treatment's effectiveness. The nursing staff can provide counseling on administration and verify adherence. In addition, nurses should educate patients not to discontinue amoxicillin when they feel better. If the nurse or pharmacist encounters any issues, they should promptly address them with the prescriber.</p>
        <p>In case of a significant overdose, triage nurses should admit the patient. Emergency physicians are responsible for evaluating and managing nephrotoxicity. Nephrologist consultation becomes necessary for hemodialysis. Consultation with a medical toxicologist or poison control center is recommended for the latest information.<xref ref-type="bibr" rid="article-17474.r45">[45]</xref> Infectious disease specialists play a crucial role in ensuring the proper management of pseudomembranous colitis resulting from inappropriate amoxicillin use. In addition, they should emphasize the importance of antimicrobial stewardship&#x02014;a coordinated program that promotes the appropriate use of antimicrobials, improves patient outcomes, diminishes microbial resistance, and mitigates the spread of infections caused by multidrug-resistant organisms.<xref ref-type="bibr" rid="article-17474.r46">[46]</xref></p>
        <p>As illustrated above, clinicians (MDs, DOs, NPs, PAs), specialists, pharmacists, nurses, and other healthcare providers should collaborate to maximize the efficacy and minimize adverse drug reactions related to amoxicillin therapy. This interprofessional team approach and antimicrobial stewardship will enhance the likelihood of more favorable patient outcomes.<xref ref-type="bibr" rid="article-17474.r47">[47]</xref></p>
      </sec>
      <sec id="article-17474.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17474&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17474">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17474/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17474">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17474.s11">
        <title>References</title>
        <ref id="article-17474.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shulman</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Bisno</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Clegg</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Van Beneden</surname>
                <given-names>C</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2012</year>
            <month>Nov</month>
            <day>15</day>
            <volume>55</volume>
            <issue>10</issue>
            <fpage>e86</fpage>
            <page-range>e86-102</page-range>
            <pub-id pub-id-type="pmid">22965026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsumoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shiotani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>DY</given-names>
              </name>
            </person-group>
            <article-title>Current and Future Treatment of Helicobacter pylori Infections.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2019</year>
            <volume>1149</volume>
            <fpage>211</fpage>
            <page-range>211-225</page-range>
            <pub-id pub-id-type="pmid">31016626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chow</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Benninger</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Brook</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Pankey</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Seleznick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Volturo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wald</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>File</surname>
                <given-names>TM</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults.</article-title>
            <source>Clin Infect Dis</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>54</volume>
            <issue>8</issue>
            <fpage>e72</fpage>
            <page-range>e72-e112</page-range>
            <pub-id pub-id-type="pmid">22438350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Piccirillo</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Chandrasekhar</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Brook</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ashok Kumar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kramper</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Orlandi</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Corrigan</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice guideline (update): adult sinusitis.</article-title>
            <source>Otolaryngol Head Neck Surg</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>152</volume>
            <issue>2 Suppl</issue>
            <fpage>S1</fpage>
            <page-range>S1-S39</page-range>
            <pub-id pub-id-type="pmid">25832968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sartelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guirao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hardcastle</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Boermeester</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ra&#x0015f;a</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ansaloni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Coccolini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Montravers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Abu-Zidan</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Bartoletti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bassetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ben-Ishay</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Biffl</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Chiara</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Chiarugi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coimbra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Rosa</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>De Simone</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Di Saverio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giannella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gkiokas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Khokha</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Labricciosa</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Lepp&#x000e4;niemi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Litvin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Negoi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pagani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Peghin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Picetti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pintar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pupelis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rubio-Perez</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sakakushev</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Segovia-Lohse</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sganga</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shelat</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sugrue</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tarasconi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tran&#x000e0;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ulrych</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Viale</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Catena</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections.</article-title>
            <source>World J Emerg Surg</source>
            <year>2018</year>
            <volume>13</volume>
            <fpage>58</fpage>
            <pub-id pub-id-type="pmid">30564282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Chlebicki</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Urinary tract infections in adults.</article-title>
            <source>Singapore Med J</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>57</volume>
            <issue>9</issue>
            <fpage>485</fpage>
            <page-range>485-90</page-range>
            <pub-id pub-id-type="pmid">27662890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hendricks</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Shadomy</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Pavia</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Rubinstein</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Holty</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Messonnier</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Pesik</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Treadwell</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Bower</surname>
                <given-names>WA</given-names>
              </name>
              <collab>Workgroup on Anthrax Clinical Guidelines</collab>
            </person-group>
            <article-title>Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">24447897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chomel</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Lyme disease.</article-title>
            <source>Rev Sci Tech</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>569</fpage>
            <page-range>569-76</page-range>
            <pub-id pub-id-type="pmid">26601457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Taubert</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Gewitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lockhart</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Baddour</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Levison</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bolger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cabell</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baltimore</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Newburger</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Strom</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Tani</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bonow</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Pallasch</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shulman</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Rowley</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ferrieri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goff</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Durack</surname>
                <given-names>DT</given-names>
              </name>
              <collab>American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee</collab>
              <collab>American Heart Association Council on Cardiovascular Disease in the Young</collab>
              <collab>American Heart Association Council on Clinical Cardiology</collab>
              <collab>American Heart Association Council on Cardiovascular Surgery and Anesthesia</collab>
              <collab>Quality of Care and Outcomes Research Interdisciplinary Working Group</collab>
            </person-group>
            <article-title>Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group.</article-title>
            <source>Circulation</source>
            <year>2007</year>
            <month>Oct</month>
            <day>09</day>
            <volume>116</volume>
            <issue>15</issue>
            <fpage>1736</fpage>
            <page-range>1736-54</page-range>
            <pub-id pub-id-type="pmid">17446442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Germack</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sedgley</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Sabbah</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Whitten</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic Use in 2016 by Members of the American Association of Endodontists: Report of a National Survey.</article-title>
            <source>J Endod</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>10</issue>
            <fpage>1615</fpage>
            <page-range>1615-1622</page-range>
            <pub-id pub-id-type="pmid">28754406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonifaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tirado-S&#x000e1;nchez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Calder&#x000f3;n</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Montes de Oca</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Torres-Camacho</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ponce</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Treatment of cutaneous actinomycosis with amoxicillin/clavulanic acid.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-64</page-range>
            <pub-id pub-id-type="pmid">27151779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernatov&#x000e1;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Samek</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pil&#x000e1;t</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ser&#x000fd;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Je&#x0017e;ek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>J&#x000e1;kl</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Siler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krzy&#x0017e;&#x000e1;nek</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zem&#x000e1;nek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hol&#x000e1;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dvo&#x00159;&#x000e1;&#x0010d;kov&#x000e1;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>R&#x0016f;&#x0017e;i&#x0010d;ka</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Following the mechanisms of bacteriostatic versus bactericidal action using Raman spectroscopy.</article-title>
            <source>Molecules</source>
            <year>2013</year>
            <month>Oct</month>
            <day>24</day>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>13188</fpage>
            <page-range>13188-99</page-range>
            <pub-id pub-id-type="pmid">24284484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weber</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Tolkoff-Rubin</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Amoxicillin and potassium clavulanate: an antibiotic combination. Mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects.</article-title>
            <source>Pharmacotherapy</source>
            <year>1984</year>
            <season>May-Jun</season>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>122</fpage>
            <page-range>122-36</page-range>
            <pub-id pub-id-type="pmid">6739312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szultka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krzeminski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jackowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buszewski</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Identification of In Vitro Metabolites of Amoxicillin in Human Liver Microsomes by LC-ESI/MS.</article-title>
            <source>Chromatographia</source>
            <year>2014</year>
            <volume>77</volume>
            <issue>15</issue>
            <fpage>1027</fpage>
            <page-range>1027-1035</page-range>
            <pub-id pub-id-type="pmid">25089048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ladumor</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Unadkat</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Prediction of Pregnancy-Induced Changes in Secretory and Total Renal Clearance of Drugs Transported by Organic Anion Transporters.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>49</volume>
            <issue>10</issue>
            <fpage>929</fpage>
            <page-range>929-937</page-range>
            <pub-id pub-id-type="pmid">34315779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reed</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.</article-title>
            <source>Postgrad Med</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>108</volume>
            <issue>7 Suppl Contemporaty</issue>
            <fpage>17</fpage>
            <page-range>17-24</page-range>
            <pub-id pub-id-type="pmid">19667545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maguigan</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Al-Shaer</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Peloquin</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2021</year>
            <month>Sep</month>
            <day>24</day>
            <volume>10</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">34680734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Damkier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Br&#x000f8;nniche</surname>
                <given-names>LMS</given-names>
              </name>
              <name>
                <surname>Korch-Frandsen</surname>
                <given-names>JFB</given-names>
              </name>
              <name>
                <surname>Broe</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>In utero exposure to antibiotics and risk of congenital malformations: a population-based study.</article-title>
            <source>Am J Obstet Gynecol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>221</volume>
            <issue>6</issue>
            <fpage>648.e1</fpage>
            <page-range>648.e1-648.e15</page-range>
            <pub-id pub-id-type="pmid">31260651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <chapter-title>Amoxicillin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>1</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">29999946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vodovar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mongardon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lepeule</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lebrun-Vignes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Biour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Netzer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Haouache</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Le Beller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dhonneur</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Dramatic Increase of Amoxicillin-Induced Crystal Nephropathy Found in a Cohort Study of French Pharmacovigilance Centers.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>62</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">29263078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mir</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pearce</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Baig-Ansari</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Qazi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Abdel-Rahman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kearns</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zaidi</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Serum amoxicillin levels in young infants (0-59 days) with sepsis treated with oral amoxicillin.</article-title>
            <source>Arch Dis Child</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>105</volume>
            <issue>12</issue>
            <fpage>1208</fpage>
            <page-range>1208-1214</page-range>
            <pub-id pub-id-type="pmid">32404437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gopal Rao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mahankali Rao</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Starke</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam-based therapy.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>697</fpage>
            <page-range>697-701</page-range>
            <pub-id pub-id-type="pmid">12615873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Akhtar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Florid Interstitial Hemorrhages: A Novel Feature of Amoxicillin-Clavulanate-Induced Acute Tubulointerstitial Nephritis.</article-title>
            <source>Am J Case Rep</source>
            <year>2021</year>
            <month>Mar</month>
            <day>15</day>
            <volume>22</volume>
            <fpage>e928989</fpage>
            <pub-id pub-id-type="pmid">33716294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrari</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fogazzi</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Garigali</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Messa</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Acute interstitial nephritis after amoxycillin with hematuria, red blood cell casts and hematuria-induced acute tubular injury.</article-title>
            <source>Clin Nephrol</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>80</volume>
            <issue>2</issue>
            <fpage>156</fpage>
            <page-range>156-60</page-range>
            <pub-id pub-id-type="pmid">22607916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Blanca</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The complex clinical picture of beta-lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams.</article-title>
            <source>Med Clin North Am</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>94</volume>
            <issue>4</issue>
            <fpage>805</fpage>
            <page-range>805-20, xii</page-range>
            <pub-id pub-id-type="pmid">20609864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r26">
          <label>26</label>
          <element-citation publication-type="book">
            <chapter-title>Amoxicillin</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>10</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">31643191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Philbrick</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ernst</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Amoxicillin-associated hemorrhagic colitis in the presence of Klebsiella oxytoca.</article-title>
            <source>Pharmacotherapy</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>27</volume>
            <issue>11</issue>
            <fpage>1603</fpage>
            <page-range>1603-7</page-range>
            <pub-id pub-id-type="pmid">17963468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alarc&#x000f3;n</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sansosti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Claver</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Botey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cister&#x000f3;-Bahima</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bartra</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Amoxicillin-Induced Aseptic Meningitis: 2 Case Reports and Appraisal of the Literature.</article-title>
            <source>J Investig Allergol Clin Immunol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>248</fpage>
            <page-range>248-250</page-range>
            <pub-id pub-id-type="pmid">31219042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curtis</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Non-chemotherapy drug-induced neutropenia: key points to manage the challenges.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2017</year>
            <month>Dec</month>
            <day>08</day>
            <volume>2017</volume>
            <issue>1</issue>
            <fpage>187</fpage>
            <page-range>187-193</page-range>
            <pub-id pub-id-type="pmid">29222255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fathallah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ouni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mokni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baccouche</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Atig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghariani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Azzabi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Denguezli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Slim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ben Salem</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>[Drug-induced vasculitis].</article-title>
            <source>Therapie</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>74</volume>
            <issue>3</issue>
            <fpage>347</fpage>
            <page-range>347-354</page-range>
            <pub-id pub-id-type="pmid">30173896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Arkell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Riezk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gilchrist</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hope</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Rawson</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Addition of probenecid to oral &#x003b2;-lactam antibiotics: a systematic review and meta-analysis.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2022</year>
            <month>Aug</month>
            <day>25</day>
            <volume>77</volume>
            <issue>9</issue>
            <fpage>2364</fpage>
            <page-range>2364-2372</page-range>
            <pub-id pub-id-type="pmid">35726853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davydov</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yermolnik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cuni</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Warfarin and amoxicillin/clavulanate drug interaction.</article-title>
            <source>Ann Pharmacother</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>367</fpage>
            <page-range>367-70</page-range>
            <pub-id pub-id-type="pmid">12639164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000e9;rez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cabrerizo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Barrio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Herrero</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tornero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baeza</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Erythema-multiforme-like eruption from amoxycillin and allopurinol.</article-title>
            <source>Contact Dermatitis</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>113</fpage>
            <page-range>113-4</page-range>
            <pub-id pub-id-type="pmid">11205391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aronson</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Ferner</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme-inducing antibiotics and hormonal contraceptives.</article-title>
            <source>BMJ Evid Based Med</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>112</fpage>
            <page-range>112-113</page-range>
            <pub-id pub-id-type="pmid">32817012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Combined Oral Contraceptives As Victims of Drug Interactions.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>718</fpage>
            <page-range>718-732</page-range>
            <pub-id pub-id-type="pmid">36963837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheon</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>IS</given-names>
              </name>
            </person-group>
            <article-title>Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility.</article-title>
            <source>J Gastroenterol Hepatol</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>10</issue>
            <fpage>1590</fpage>
            <page-range>1590-5</page-range>
            <pub-id pub-id-type="pmid">16928222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Joung</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer.</article-title>
            <source>Front Oncol</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>570077</fpage>
            <pub-id pub-id-type="pmid">33868985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thong</surname>
                <given-names>BY</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced Stevens Johnson syndrome and toxic epidermal necrolysis: Interpreting the systematic reviews on immunomodulatory therapies.</article-title>
            <source>Asia Pac Allergy</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>72</fpage>
            <page-range>72-76</page-range>
            <pub-id pub-id-type="pmid">37388817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shenoy</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Macy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and Management of Penicillin Allergy: A Review.</article-title>
            <source>JAMA</source>
            <year>2019</year>
            <month>Jan</month>
            <day>15</day>
            <volume>321</volume>
            <issue>2</issue>
            <fpage>188</fpage>
            <page-range>188-199</page-range>
            <pub-id pub-id-type="pmid">30644987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reed</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of amoxicillin and clavulanate.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>949</fpage>
            <page-range>949-54</page-range>
            <pub-id pub-id-type="pmid">8895939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sutter</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>R&#x000fc;egg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tschudin-Sutter</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Seizures as adverse events of antibiotic drugs: A systematic review.</article-title>
            <source>Neurology</source>
            <year>2015</year>
            <month>Oct</month>
            <day>13</day>
            <volume>85</volume>
            <issue>15</issue>
            <fpage>1332</fpage>
            <page-range>1332-41</page-range>
            <pub-id pub-id-type="pmid">26400582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cerba</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Grosjean</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Forestier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rogeaux</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bally</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Croze</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maynard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Philit</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Fourcade</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Amoxicillin induced crystal nephropathy : Monitoring of residual plasma levels].</article-title>
            <source>Nephrol Ther</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>428</fpage>
            <page-range>428-433</page-range>
            <pub-id pub-id-type="pmid">34034971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maher</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Principles of dialysis and dialysis of drugs.</article-title>
            <source>Am J Med</source>
            <year>1977</year>
            <month>Apr</month>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>475</fpage>
            <page-range>475-81</page-range>
            <pub-id pub-id-type="pmid">851116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adkinson</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Mendelson</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Ressler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Keogh</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Penicillin minor determinants: History and relevance for current diagnosis.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>121</volume>
            <issue>5</issue>
            <fpage>537</fpage>
            <page-range>537-544</page-range>
            <pub-id pub-id-type="pmid">30248407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spiller</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Griffith</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>The value and evolving role of the U.S. Poison Control Center System.</article-title>
            <source>Public Health Rep</source>
            <year>2009</year>
            <season>May-Jun</season>
            <volume>124</volume>
            <issue>3</issue>
            <fpage>359</fpage>
            <page-range>359-63</page-range>
            <pub-id pub-id-type="pmid">19445410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dyar</surname>
                <given-names>OJ</given-names>
              </name>
              <name>
                <surname>Huttner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schouten</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pulcini</surname>
                <given-names>C</given-names>
              </name>
              <collab>ESGAP (ESCMID Study Group for Antimicrobial stewardshiP)</collab>
            </person-group>
            <article-title>What is antimicrobial stewardship?</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>793</fpage>
            <page-range>793-798</page-range>
            <pub-id pub-id-type="pmid">28882725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17474.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nathwani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Varghese</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stephens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ansari</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Charbonneau</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review.</article-title>
            <source>Antimicrob Resist Infect Control</source>
            <year>2019</year>
            <volume>8</volume>
            <fpage>35</fpage>
            <pub-id pub-id-type="pmid">30805182</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
